Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents
NCT02907359 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 13, 2017
- Completion date
- November 30, 2020
- Enrollment
- 417 (actual)
- Sites
- 112
Conditions
As the registry lists them; a condition with its own page is linked.